MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
381.82%
Quick Ratio
381.82%
Cash Ratio
75.76%
Unit: Million (M) dollars
Assets Breakdown
    • Marketable securities
    • Cash and cash equivalents
    • Long-term marketable securities
    • Others
Liabilities Breakdown
    • Common stock and additional paid...
    • Accumulated deficit
    • Other noncurrent liabilities
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
150
201
222
238
Marketable securities
552
621
759
593
Receivable from collaboration partners
36
3
11
11
Prepaid expenses and other current assets
18
19
15
15
Total current assets
756
844
1,007
857
Long-term marketable securities
73
54
29
10
Property and equipment, net
36
38
40
42
Other noncurrent assets
59
61
63
65
Total assets
924
997
1,139
974
Accounts payable (12 and 24 to a related party)
34
39
42
42
Deferred revenue (11 and 35 to a related party)
19
34
35
52
Other current liabilities
145
136
154
141
Total current liabilities
198
209
231
235
Deferred revenue, noncurrent (19 and 43 to a related party)
37
45
43
53
Long-term debt
101
100
99
98
Other noncurrent liabilities
124
119
135
152
Common stock and additional paid-in capital 0.0001 par value per share 400.0 shares authorized 127.0 shares in 2026 and 125.3 shares in 2025 issued and outstanding
2,169
2,138
2,116
1,815
Accumulated deficit
-1,704
-1,613
-1,485
-1,379
Accumulated other comprehensive loss
-1
-1
-
-
Total stockholders equity
464
524
631
436
Total liabilities and stockholders equity
924
997
1,139
974
Unit: Million (M) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Marketable securities$552M (-16.74%↓ Y/Y)Cash and cashequivalents$150M (-39.52%↓ Y/Y)Receivable fromcollaboration partners$36M (140.00%↑ Y/Y)Prepaid expenses andother current assets$18M (-10.00%↓ Y/Y)Total current assets$756M (-20.08%↓ Y/Y)Long-term marketablesecurities$73M (356.25%↑ Y/Y)Other noncurrentassets$59M (-14.49%↓ Y/Y)Property and equipment,net$36M (-18.18%↓ Y/Y)Total assets$924M (-14.05%↓ Y/Y)Total liabilities andstockholders equity$924M (-14.05%↓ Y/Y)Total stockholdersequity$464M (-15.48%↓ Y/Y)Total currentliabilities$198M (-5.71%↓ Y/Y)Other noncurrentliabilities$124M (-22.01%↓ Y/Y)Long-term debt$101M (4.12%↑ Y/Y)Deferred revenue,noncurrent (19 and 43 to a...$37M (-38.33%↓ Y/Y)Accumulated deficit-$1,704M (-36.98%↓ Y/Y)Accumulated othercomprehensive loss-$1M Common stock andadditional paid-in capital...$2,169M (20.97%↑ Y/Y)Other currentliabilities$145M (31.82%↑ Y/Y)Accounts payable (12 and24 to a related...$34M (17.24%↑ Y/Y)Deferred revenue (11 and35 to a related...$19M (-73.24%↓ Y/Y)

Arcus Biosciences, Inc. (RCUS)

Arcus Biosciences, Inc. (RCUS)